OrthoPediatrics’ (KIDS) Market Outperform Rating Reaffirmed at JMP Securities

JMP Securities reissued their market outperform rating on shares of OrthoPediatrics (NASDAQ:KIDS) in a research note issued to investors on Tuesday morning, Benzinga reports. The firm currently has a $50.00 price objective on the stock.

A number of other brokerages have also recently weighed in on KIDS. Truist Financial cut shares of OrthoPediatrics from a buy rating to a hold rating and dropped their target price for the stock from $39.00 to $31.00 in a report on Thursday, January 25th. Needham & Company LLC reiterated a buy rating and set a $37.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, April 10th.

OrthoPediatrics Stock Up 3.3 %

NASDAQ:KIDS opened at $34.70 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.90 and a current ratio of 5.44. The company has a market capitalization of $825.51 million, a price-to-earnings ratio of -37.72 and a beta of 1.16. OrthoPediatrics has a one year low of $23.10 and a one year high of $48.47. The stock has a 50-day simple moving average of $28.80 and a 200 day simple moving average of $29.04.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Wednesday, March 6th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.05. The company had revenue of $37.61 million during the quarter, compared to analyst estimates of $37.59 million. OrthoPediatrics had a negative return on equity of 5.03% and a negative net margin of 14.10%. Sell-side analysts predict that OrthoPediatrics will post -1.34 EPS for the current fiscal year.

Insider Buying and Selling at OrthoPediatrics

In related news, CFO Fred Hite sold 3,195 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $27.59, for a total value of $88,150.05. Following the sale, the chief financial officer now owns 94,072 shares of the company’s stock, valued at approximately $2,595,446.48. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CEO David R. Bailey sold 3,213 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $88,646.67. Following the completion of the transaction, the chief executive officer now owns 139,384 shares of the company’s stock, valued at $3,845,604.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Fred Hite sold 3,195 shares of the firm’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $27.59, for a total value of $88,150.05. Following the transaction, the chief financial officer now directly owns 94,072 shares in the company, valued at $2,595,446.48. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,253 shares of company stock worth $477,375. 31.80% of the stock is owned by insiders.

Hedge Funds Weigh In On OrthoPediatrics

Several large investors have recently bought and sold shares of the stock. Brown Advisory Inc. increased its stake in shares of OrthoPediatrics by 1.6% during the fourth quarter. Brown Advisory Inc. now owns 1,628,779 shares of the company’s stock valued at $52,952,000 after acquiring an additional 25,337 shares during the period. Braidwell LP increased its position in shares of OrthoPediatrics by 4.7% during the 4th quarter. Braidwell LP now owns 1,107,770 shares of the company’s stock valued at $36,014,000 after purchasing an additional 50,000 shares during the period. Vanguard Group Inc. raised its stake in shares of OrthoPediatrics by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 860,804 shares of the company’s stock worth $27,546,000 after buying an additional 10,861 shares in the last quarter. Granahan Investment Management LLC lifted its holdings in shares of OrthoPediatrics by 30.0% in the fourth quarter. Granahan Investment Management LLC now owns 769,245 shares of the company’s stock valued at $25,008,000 after buying an additional 177,640 shares during the period. Finally, New York State Common Retirement Fund boosted its stake in OrthoPediatrics by 1.4% during the third quarter. New York State Common Retirement Fund now owns 557,462 shares of the company’s stock valued at $17,839,000 after buying an additional 7,429 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.